Trial Profile
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Retinal disorders
- Focus Therapeutic Use
- 03 Oct 2023 Status changed from suspended to discontinued.
- 16 Sep 2022 Planned End Date changed from 1 Feb 2024 to 1 Feb 2030.
- 16 Sep 2022 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2030.